


Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE ALTER 40 mg/12.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg film-coated tablets EFG
Olmesartan/Hydrochlorothiazide Alter 40 mg/25 mg film-coated tablets EFG
Olmesartan medoxomil/Hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you have any further questions, ask your doctor or pharmacist.
Contents of the pack and other information
Contents of the pack and further information
Olmesartan/Hydrochlorothiazide Alter contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension):
Olmesartan/Hydrochlorothiazide Alter will only be given if treatment with Olmesartan (olmesartan medoxomil) alone has not adequately controlled your blood pressure. The combination of both active substances in Olmesartan/Hydrochlorothiazide Alter helps to lower blood pressure more than either substance on its own.
You may already be taking medicines to treat high blood pressure, but your doctor may think it is necessary for you to take Olmesartan/Hydrochlorothiazide Alter to lower it further.
High blood pressure can be controlled with medicines such as Olmesartan/Hydrochlorothiazide Alter tablets. Your doctor may also have recommended that you make some changes to your lifestyle, such as losing weight, stopping smoking, reducing alcohol intake, and reducing the amount of salt in your diet. Your doctor may also have recommended that you exercise regularly, such as walking or swimming. It is important to follow your doctor's advice.
Do not take Olmesartan/Hydrochlorothiazide Alter
If you think any of these apply to you, or if you are not sure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Talk to your doctor before you start taking Olmesartan/Hydrochlorothiazide Alter.
Talk to your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Olmesartan/Hydrochlorothiazide Alter. Your doctor will decide whether to continue treatment. Do not stop taking Olmesartan/Hydrochlorothiazide Alter on your own.
Before taking the tablets, tell your doctor if you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels at regular intervals.
See also the information under the heading “Do not take Olmesartan/Hydrochlorothiazide Alter”.
Before taking the tablets, tell your doctorif you have any of the following health problems:
Tell your doctor if you experience any of the following symptoms:
Your doctor may want to see you more often and perform some tests if you have any of these problems.
Olmesartan/Hydrochlorothiazide Alter may cause increased levels of lipids and uric acid (which causes gout - painful swelling of the joints) in the blood. Your doctor will probably want to perform a blood test from time to time to check for these possible changes. There may be a change in the levels of certain chemicals in the blood called electrolytes. Your doctor will probably want to perform a blood test from time to time to check for this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, sleepiness or restlessness, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms. As with any other medicine that lowers blood pressure, excessively low blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
If you are going to have parathyroid function tests, you should stop taking Olmesartan/Hydrochlorothiazide Alter before these tests are performed.
Athletes are informed that this medicine contains a component that may give a positive doping test result.
You must tell your doctor if you are pregnant or think you might be pregnant. It is not recommended to take Olmesartan/Hydrochlorothiazide Alter during pregnancy, and you must not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken after the third month of pregnancy.
Children and adolescents
Olmesartan/Hydrochlorothiazide Alter is not recommended for children and adolescents under 18 years of age.
Taking Olmesartan/Hydrochlorothiazide Alter with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist about any of the following medicines:
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Olmesartan/Hydrochlorothiazide Alter” and “Warnings and precautions”).
Taking Olmesartan/Hydrochlorothiazide Alter with food and drink
Olmesartan/Hydrochlorothiazide Alter can be taken with or without food.
Be careful when drinking alcohol while taking Olmesartan/Hydrochlorothiazide Alter, as some people feel weak or dizzy. If this happens, do not drink any alcohol, including wine, beer, or alcoholic drinks.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Olmesartan/Hydrochlorothiazide Alter is somewhat less in black patients.
Pregnancy and breastfeeding
Pregnancy
You must tell your doctor if you are pregnant or think you might be pregnant. Your doctor will advise you to stop taking Olmesartan/Hydrochlorothiazide Alter before you become pregnant or as soon as you know you are pregnant, and will advise you to take a different medicine instead of Olmesartan/Hydrochlorothiazide Alter. It is not recommended to take Olmesartan/Hydrochlorothiazide Alter during pregnancy, and you must not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken after the third month of pregnancy.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. Olmesartan/Hydrochlorothiazide Alter is not recommended for women who are breastfeeding, and your doctor may choose a different treatment if you want to breastfeed.
If you are pregnant or breastfeeding, think you might be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel sleepy or dizzy while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have gone away. Talk to your doctor.
Olmesartan/Hydrochlorothiazide Alter contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
Follow exactly the instructions of your doctor for taking this medicine. If you are not sure, talk to your doctor or pharmacist again.
The recommended doseis one Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg tablet per day. If your blood pressure is not adequately controlled, your doctor may change the dose to one Olmesartan/Hydrochlorothiazide Alter 40 mg/25 mg tablet per day.
Take the tablets with water. If possible, take your dose at the same time each day, for example, at breakfast time. It is important that you keep taking Olmesartan/Hydrochlorothiazide Alter until your doctor tells you to stop.
If you take more Olmesartan/Hydrochlorothiazide Alter than you should
If you take more tablets than you should or if a child accidentally takes one or more tablets, contact your doctor or go to the nearest hospital emergency department immediately and take the medicine pack with you.
In case of overdose or accidental ingestion, talk to your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, stating the medicine and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide Alter
If you forget to take a dose, take your usual dose the next day. Do nottake a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide Alter
It is important to continue taking Olmesartan/Hydrochlorothiazide Alter unless your doctor tells you to stop.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
However, the following adverse effects can be serious:
Olmesartan/Hydrochlorothiazide Alter is a combination of two active ingredients. The following information first describes the adverse effects reported so far with the Olmesartan/Hydrochlorothiazide Alter combination (in addition to those already mentioned) and, secondly, the known adverse effects of the two active ingredients separately.
These are other known adverse effects of Olmesartan/Hydrochlorothiazide Alter so far:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Common adverse effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid and intense heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erection problems in men, blood in urine.
Some changes in blood tests have also been observed infrequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare adverse effects (may affect up to 1 in 1,000 people):
Feeling of discomfort, altered consciousness, skin swelling (hives), acute kidney failure.
Some changes in blood test results have also been observed rarely, including:
Increased blood urea nitrogen, decreased hemoglobin and hematocrit values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Additional adverse effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not with Olmesartan/Hydrochlorothiazide Alter or at a higher frequency:
Olmesartan medoxomil:
Common adverse effects (may affect up to 1 in 10 people):
Bronchitis, cough, nasal congestion and secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Some changes in blood test results have also been observed frequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased liver or muscle function test values.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid allergic reactions that can affect the whole body and cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, angina (chest pain or discomfort known as angina pectoris), feeling of discomfort, allergic skin rash, itching, exanthema (skin rash), skin swelling (hives).
Some changes in blood test results have also been observed infrequently, including:
Reduction in the number of a type of blood cell called platelets (thrombocytopenia).
Rare adverse effects (may affect up to 1 in 1,000 people):
Worsening of kidney function, lack of energy.
Some changes in blood test results have also been observed rarely, including: increased potassium in the blood.
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Hydrochlorothiazide:
Very common adverse effects (may affect more than 1 in 10 people):
Changes in blood tests, including: increased fat in the blood and uric acid levels.
Common adverse effects (may affect up to 1 in 10 people):
Feeling of confusion, abdominal pain, stomach discomfort, feeling of bloating, diarrhea, nausea, vomiting, constipation, glucose in urine.
Some changes in blood test results have also been observed, including:
Increased creatinine, urea, calcium, and blood sugar levels, decreased chloride, potassium, magnesium, and sodium levels in the blood. Increased serum amylase (hyperamylasemia).
Uncommon adverse effects (may affect up to 1 in 100 people):
Decreased or lost appetite, severe breathing difficulties, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions due to light sensitivity, itching, purple spots or patches on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare adverse effects (may affect up to 1 in 1,000 people):
Inflammation and pain of the salivary glands, decreased number of white blood cells, decreased number of platelets in the blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness, seizures (convulsions), yellowish perception of objects when looking at them, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in the lungs, pancreatitis, jaundice, infection in the gallbladder, lupus erythematosus symptoms such as skin rash, joint pain, and cold hands and fingers, allergic skin reactions, skin peeling and blisters, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness (sometimes causing movement disorders).
Very rare adverse effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally reduced level of chloride in the blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus), acute breathing difficulties (signs include severe breathing difficulties, fever, weakness, and confusion).
Adverse effects of unknown frequency (cannot be estimated from available data):
Skin and lip cancer (non-melanoma skin cancer).
Decreased vision or eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
No special storage conditions are required.
Do not use this medicine after the expiration date shown on the packaging and on the blister pack after "EXP". The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide Alter
Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg: each film-coated tablet contains 40 mg of olmesartan medoxomil and 12.5 mg of hydrochlorothiazide.
Olmesartan/Hydrochlorothiazide Alter 40 mg/25 mg: each film-coated tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg also contains yellow iron oxide (E172).
Olmesartan/Hydrochlorothiazide Alter 40 mg/25 mg also contains red iron oxide (E172).
Appearance of the Product and Package Contents
Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg: film-coated tablets, yellow, oblong, biconvex.
Olmesartan/Hydrochlorothiazide Alter 40 mg/25 mg: film-coated tablets, dark pink, oblong, biconvex.
The tablets are available in packs of 14, 28, 30, 56, and 90 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Laboratorios Alter, S.A.
C/ Mateo Inurria 30
28036 Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain Olmesartan/Hydrochlorothiazide Alter 40 mg/12.5 mg / 40 mg/25 mg film-coated tablets EFG
Italy Olmesartan medoxomil and hydrochlorothiazide Alter
Portugal Olmesartan medoxomil + hydrochlorothiazide Alter 40 mg + 12.5 mg / 40 mg + 25 mg film-coated tablets MG
Date of the last revision of this leaflet: February 2025.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE ALTER 40 mg/12.5 mg FILM-COATED TABLETS in October, 2025 is around 20.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE ALTER 40 mg/12.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.